Evidence map›Paper›PMID 35419377›Full record

ArticleFrontiers in medicine2022

Identification of 27 Novel Variants in Genes

Agne Cerkauskaite, Judy Savige, Karolina Janonyte, Ieva Jeremiciute, Marius Miglinas, Edita Kazenaite, Arvydas Laurinavicius, Rasa Strupaite-Sileikiene, Vija Vainutiene, Birute Burnyte and 5 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.7field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Lithuanian Study onInternational journal of molecular sciences · 2025
    Article
  4. A Deeper Insight intoMolecular syndromology · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 3 countries.

Agne CerkauskaiteInstitute of Biomedical Sciences, Faculty of Medicine, Vilnius University, Vilnius, Lithuania.
Judy SavigeDepartment of Medicine (Melbourne Health and Northern Health), Royal Melbourne Hospital, The University of Melbourne, Parkville, VIC, Australia.
Karolina JanonyteFaculty of Medicine, Vilnius University, Vilnius, Lithuania.
Ieva JeremiciuteFaculty of Medicine, Vilnius University, Vilnius, Lithuania.
Marius MiglinasInstitute of Clinical Medicine, Faculty of Medicine, Vilnius University, Vilnius, Lithuania.
Edita KazenaiteInstitute of Biomedical Sciences, Faculty of Medicine, Vilnius University, Vilnius, Lithuania.
Arvydas LaurinaviciusInstitute of Biomedical Sciences, Faculty of Medicine, Vilnius University, Vilnius, Lithuania.
Rasa Strupaite-SileikieneInstitute of Clinical Medicine, Faculty of Medicine, Vilnius University, Vilnius, Lithuania.
Vija VainutieneCentre of Ear, Nose and Throat Diseases, Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania.
Birute BurnyteInstitute of Biomedical Sciences, Faculty of Medicine, Vilnius University, Vilnius, Lithuania.
Augustina JankauskieneInstitute of Clinical Medicine, Faculty of Medicine, Vilnius University, Vilnius, Lithuania.
Arndt RolfsAlbrecht Kossel Institute for Neuroregeneration, University of Rostock, Rostock, Germany.
Peter BauerCENTOGENE GmbH, Rostock, Germany.
Sabine SchröderCENTOGENE GmbH, Rostock, Germany.
Rimante CerkauskieneInstitute of Clinical Medicine, Faculty of Medicine, Vilnius University, Vilnius, Lithuania.
Vilnius University · LTCentogene (Germany) · DEUniversity of Melbourne · AUUniversity of Rostock · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Alport syndrome (AS) is an inherited disorder characterized by hematuria, proteinuria, and kidney function impairment, and frequently associated with extrarenal manifestations. Pathogenic variants in Methods: In this study molecular analysis by next generation sequencing (NGS) was performed on individuals from a Lithuanian cohort, with suspected AS. The presence of AS was assessed by reviewing clinical evidence of hematuria, proteinuria, chronic kidney disease (CKD), kidney failure (KF), a family history of AS or persistent hematuria, and specific histological lesions in the kidney biopsy such as thinning or lamellation of the glomerular basement membrane (GBM). Clinical, genetic, laboratory, and pathology data were reviewed. The novelty of the Results: Molecular testing of 171 suspected individuals led to the detection of 99 individuals with 44 disease causing variants including 27, previously undescribed changes, with the frequency of 9/27 (33,3%) in genes Conclusion: Genotype-phenotype correlation analysis suggested that some variants demonstrated intra-familial phenotypic variability. These novel variants represented more than half of all the variants found in a cohort of 171 individuals from 109 unrelated families who underwent testing. Our study expands the knowledge of the genetic and phenotypic spectrum for AS.

Indexed as

Alport syndromeCOL4A3COL4A4COL4A5 variantsdigenic inheritancegenotype-phenotype correlationnovel

Identifiers

PMID35419377
PMCPMC8995700
OpenAlexW4220794625

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.